Sanofi
Ties-up With Emcure Pharma To Market Its Oncology Portfolio In India
Sanofi India Ltd.
announced that it has entered into a marketing and distribution agreement with
Emcure Pharmaceuticals for its oncology portfolio in India.
Under the agreement terms,
while Sanofi will continue to own its oncology range, comprising 4 brands
namely Taxotere, Jevtana, Fludara and Fasturtec, Emcure will market and
distribute these brands through its Specialty Unit.
Commenting on the
partnership, Shailesh Ayyangar, Vice President -South Asia and Managing
Director -Sanofi India and Sanofi -Synthelabo (India) Ltd. said, "Sanofi
is highly committed to the field of Oncology. Realizing that managing the
complexities of cancer necessitates the availability of a wide range of products
and supporting therapies, we found that combining our efforts and product range
with that of Emcure Oncology, makes immense sense for both companies. Doctors
and patients will now have access -'under one roof' -to one of the most
comprehensive and complementing Oncology portfolios in India. Sanofi will
continue to provide strong scientific and medical support to Emcure's already
well-established and fast growing Oncology business."
Emcure Pharmaceuticals
Managing Director Satish Mehta stated, "We are delighted to be identified
as the partner-of-choice by Sanofi in India; and for being entrusted with such
a prestigious global Oncology portfolio. We believe that the coming together of
Sanofi's innovative oncology range with Emcure's oncology portfolio empowers us
to provide an even wider array of value driven healthcare solutions. We are
extremely optimistic about its prospects and committed to creating a long-term
partnership with Sanofi."
At the BSE, Sanofi India
shares are currently trading at Rs.2,886.00, up 0.27 percent from the previous
close.
No comments:
Post a Comment